CADILLAC
This article was originally published in The Gray Sheet
Executive Summary
Stenting alone demonstrated a statistically significant lower rate of major adverse cardiac events compared with balloon angioplasty in results presented at the Transcatheter Cardiovascular Therapeutics 2000 conference in Washington, D.C. Oct. 19. The CADILLAC trial, which used Guidant's Multi-link and Multi-link Duet stents, enrolled 2,665 heart attack patients at 74 centers worldwide